Role of lncRNAs in prostate cancer development and progression

Biological Chemistry

Volumn 395, Issue 11, 2014, Pages 1275-1290

  Weiss, Melanie ^a   Plass, Christoph ^a   Gerhauser, Clarissa ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

androgen receptor; chromatin remodeling; epigenetics; polycomb repressive complex (PRC); pseudogene; PTEN

Indexed keywords

ANDROGEN RECEPTOR; CARRIER PROTEINS AND BINDING PROTEINS; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH ARREST SPECIFIC PROTEIN 5; LONG UNTRANSLATED RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN KINASE B; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA BINDING; DNA METHYLATION; DNA RESPONSIVE ELEMENT; EPIGENETICS; GENE AMPLIFICATION; GENE CONTROL; GENOME IMPRINTING; HUMAN; LNCAP CELL LINE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; PSEUDOGENE; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; ANIMAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; RNA, LONG NONCODING; SIGNAL TRANSDUCTION;

EID: 84907651988     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2014-0201     Document Type: Review

References (77)

1. Arab, K., Park, Y.J., Lindroth, A.M., Schafer, A., Oakes, C., Weichenhan, D., Lukanova, A., Lundin, E., Risch, A., Meister, M., et al. (2014). Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. Mol. Cell. 55, 604-614.
2. Auprich, M., Chun, F.K., Ward, J.F., Pummer, K., Babaian, R., Augustin, H., Luger, F., Gutschi, S., Budaus, L., Fisch, M., et al. (2011). Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur. Urol. 59, 96-105.
3. Beckedorff, F.C., Ayupe, A.C., Crocci-Souza, R., Amaral, M.S., Nakaya, H.I., Soltys, D.T., Menck, C.F., Reis, E.M., and Verjovski-Almeida, S. (2013). The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 9, e1003705.
4. Berteaux, N., Lottin, S., Adriaenssens, E., Van Coppenolle, F., Leroy, X., Coll, J., Dugimont, T., and Curgy, J.J. (2004). Hormonal regulation of H19 gene expression in prostate epithelial cells. J. Endocrinol. 183, 69-78.
5. Borowsky, M., Lee, J.T., Ohsumi, T.K., Sarma, K., and Zhao, J. (2012). Polycomb-associated non-coding rnas. WO 2012087983 A1.
6. Bray, F., Ren, J.S., Masuyer, E., and Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer 132, 1133-1145.
7. Bussemakers, M.J., van Bokhoven, A., Verhaegh, G.W., Smit, F.P., Karthaus, H.F., Schalken, J.A., Debruyne, F.M., Ru, N., and Isaacs, W.B. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5979.
8. Chinnaiyan, A., Prensner, J., and Iyer, M. (2012). ncRNA and uses thereof. WO 2012068383 A2.
9. Chung, S., Nakagawa, H., Uemura, M., Piao, L., Ashikawa, K., Hosono, N., Takata, R., Akamatsu, S., Kawaguchi, T., Morizono, T., et al. (2011). Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 102, 245-252.
10. Crea, F., Watahiki, A., Quagliata, L., Xue, H., Pikor, L., Parolia, A., Wang, Y., Lin, D., Lam, W.L., Farrar, W.L., et al. (2014). Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 5, 764-774.
11. Cui, Z., Ren, S., Lu, J., Wang, F., Xu, W., Sun, Y., Wei, M., Chen, J., Gao, X., Xu, C., et al. (2013). The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol. Oncol. 31, 1117-1123.
12. Du, Z., Fei, T., Verhaak, R.G., Su, Z., Zhang, Y., Brown, M., Chen, Y., and Liu, X.S. (2013). Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat. Struct. Mol. Biol. 20, 908-913.
13. Ebert, M.S., Neilson, J.R., and Sharp, P.A. (2007). MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726.
14. Esteller, M. (2011). Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861-874.
15. Ferreira, L.B., Palumbo, A., de Mello, K.D., Sternberg, C., Caetano, M.S., de Oliveira, F.L., Neves, A.F., Nasciutti, L.E., Goulart, L.R., and Gimba, E.R. (2012). PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer 12, 507.
16. Fu, M., Wang, C., Reutens, A.T., Wang, J., Angeletti, R.H., Siconolfi- Baez, L., Ogryzko, V., Avantaggiati, M.L., and Pestell, R.G. (2000). p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 275, 20853-20860.
17. Fu, V.X., Schwarze, S.R., Kenowski, M.L., Leblanc, S., Svaren, J., and Jarrard, D.F. (2004). A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J. Biol. Chem. 279, 52218-52226.
18. Fu, X., Ravindranath, L., Tran, N., Petrovics, G., and Srivastava, S. (2006). Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 25, 135-141.
19. Fu, V.X., Dobosy, J.R., Desotelle, J.A., Almassi, N., Ewald, J.A., Srinivasan, R., Berres, M., Svaren, J., Weindruch R., and Jarrard, D.F. (2008). Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res. 68, 6797-6802.
20. Grasso, C.S., Wu, Y.M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., Quist, M.J., Jing, X., Lonigro, R.J., Brenner, J.C., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243.
21. Gregory, R.I. and Shiekhattar, R. (2004). Chromatin modifiers and carcinogenesis. Trends Cell. Biol. 14, 695-702.
22. Groskopf, J., Aubin, S.M., Deras, I.L., Blase, A., Bodrug, S., Clark, C., Brentano, S., Mathis, J., Pham, J., Meyer, T. et al. (2006). APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52, 1089-1095.
23. Gutschner, T., Hammerle, M., Eissmann, M., Hsu, J., Kim, Y., Hung, G., Revenko, A., Arun, G., Stentrup, M., Gross, M., et al. (2013). The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73, 1180-1189.
24. Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., Huarte, M., Zuk, O., Carey, B.W., Cassady, J.P., et al. (2009). Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223-227.
25. Jelinic, P., Mueller, J.J., Olvera, N., Dao, F., Scott, S.N., Shah, R., Gao, J., Schultz, N., Gonen, M., Soslow, R.A., et al. (2014). Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat. Genet. 46, 424-426.
26. Jeronimo, C., Bastian, P.J., Bjartell, A., Carbone, G.M., Catto, J.W., Clark, S.J., Henrique, R., Nelson, W.G., and Shariat, S.F. (2011). Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 60, 753-766.
27. Ji, P., Diederichs, S., Wang, W., Boing, S., Metzger, R., Schneider, P.M., Tidow, N., Brandt, B., Buerger, H., Bulk, E., et al. (2003). MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031-8041.
28. Johnsson, P., Ackley, A., Vidarsdottir, L., Lui, W.O., Corcoran, M., Grander, D., and Morris, K.V. (2013). A pseudogene long-noncoding- RNA network regulates PTEN transcription and translation in human cells. Nat. Struct. Mol. Biol. 20, 440-446.
29. Kino, T., Hurt, D.E., Ichijo, T., Nader, N., and Chrousos, G.P. (2010). Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal 3, ra8.
30. Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Porter Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., et al. (2013). Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110, 7922-7927.
31. Knutson, S.K., Kawano, S., Minoshima, Y., Warholic, N.M., Huang, K.C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014). Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13, 842-854.
32. Kotake, Y., Nakagawa, T., Kitagawa, K., Suzuki, S., Liu, N., Kitagawa, M., and Xiong, Y. (2011). Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30, 1956-1962.
33. Lee, J.T. (2012). Epigenetic regulation by long noncoding RNAs. Science 338, 1435-1439.
34. Leyten, G.H., Hessels, D., Jannink, S.A., Smit, F.P., de Jong, H., Cornel, E.B., de Reijke, T.M., Vergunst, H., Kil, P., Knipscheer, B.C., et al. (2014). Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 65, 5342.
35. Malik, R., Patel, L., Prensner, J.R., Shi, Y., Iyer, M.K., Subramaniyan, S., Carley, A., Niknafs, Y.S., Sahu, A., Han, S., et al. (2014). The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol. Cancer Res. 12, 1081-1087.
36. Maruyama, R. and Suzuki, H. (2012). Long noncoding RNA involvement in cancer. BMB Rep. 45, 604-611.
37. Mercer, T.R. and Mattick, J.S. (2013). Structure and function of long noncoding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol. 20, 300-307.
38. Mills, I.G. (2014). Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat. Rev. Cancer 14, 187-198.
39. Mourtada-Maarabouni, M., Pickard, M.R., Hedge, V.L., Farzaneh, F., and Williams, G.T. (2009). GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 28, 195-208.
40. Orfanelli, U., Jachetti, E., Chiacchiera, F., Grioni, M., Brambilla, P., Briganti, A., Freschi, M., Martinelli-Boneschi, F., Doglioni, C., Montorsi, F., et al. (2014). Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene 10.1038/onc.2014.144.
41. Palakurthy, R.K., Wajapeyee, N., Santra, M.K., Gazin, C., Lin, L., Gobeil, S., and Green, M.R. (2009). Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol. Cell 36, 219-230.
42. Petrovics, G., Zhang, W., Makarem, M., Street, J.P., Connelly, R., Sun, L., Sesterhenn, I.A., Srikantan, V., Moul, J.W., and Srivastava, S. (2004). Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 23, 605-611.
43. Phin, S., Moore, M.W., and Cotter, P.D. (2013). Genomic rearrangements of in prostate cancer. Front. Oncol. 3, 240.
44. Pickard, M.R., Mourtada-Maarabouni, M., and Williams, G.T. (2013). Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim. Biophys. Acta 1832, 1613-1623.
45. Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M.S., Hobbs, R.M., Sportoletti, P., Varmeh, S., Egia, A., Fedele G., et al. (2010a). Identification of the miR-106b+25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 3, ra29.
46. Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W.J., and Pandolfi, P.P. (2010b). A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033-1038.
47. Ponting, C.P., Oliver, P.L., and Reik, W. (2009). Evolution and functions of long noncoding RNAs. Cell 136, 629-641.
48. Prensner, J.R. and Chinnaiyan, A.M. (2011). The emergence of lncRNAs in cancer biology. Cancer Discov. 1, 391-407.
49. Prensner, J.R., Iyer, M.K., Balbin, O.A., Dhanasekaran, S.M., Cao, Q., Brenner, J.C., Laxman, B., Asangani, I.A., Grasso, C.S., Kominsky, H.D., et al. (2011). Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29, 742-749.
50. Prensner, J.R., Iyer, M.K., Sahu, A., Asangani, I.A., Cao, Q., Patel, L., Vergara, I.A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013). The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 45, 1392-1398.
51. Prensner, J.R., Chen, W., Iyer, M.K., Cao, Q., Ma, T., Han, S., Sahu, A., Malik, R., Wilder-Romans, K., Navone, N., et al. (2014a). PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 74, 1651-1660.
52. Prensner, J.R., Sahu, A., Iyer, M.K., Malik, R., Chandler, B., Asangani, I.A., Poliakov, A., Vergara, I.A., Alshalalfa, M., Jenkins, R.B., et al. (2014b). The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 30, 1434-1438.
53. Ren, S., Peng, Z., Mao, J.H., Yu, Y., Yin, C., Gao, X., Cui, Z., Zhang, J., Yi, K., Xu, W., et al. (2012). RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 22, 806-821.
54. Ren, S., Liu, Y., Xu, W., Sun, Y., Lu, J., Wang, F., Wei, M., Shen, J., Hou, J., Gao, X., et al. (2013a). Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J. Urol. 190, 2278-2287.
55. Ren, S., Wang, F., Shen, J., Sun, Y., Xu, W., Lu, J., Wei, M., Xu, C., Wu, C., Zhang, Z., et al. (2013b). Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur. J. Cancer 49, 2949-2959.
56. Ribarska, T., Goering, W., Droop, J., Bastian, K.M., Ingenwerth, M., and Schulz, W.A. (2014). Deregulation of an imprinted gene network in prostate cancer. Epigenetics 9, 704-717.
57. Roberts, C.W. and Orkin, S.H. (2004). The SWI/SNF complex - chromatin and cancer. Nat. Rev. Cancer 4, 133-142.
58. Romanuik, T.L., Wang, G., Morozova, O., Delaney, A., Marra, M.A., and Sadar, M.D. (2010). LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med. Genomics 3, 43.
59. Sander, J.D. and Joung, J.K. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347-355.
60. Sarma, K., Levasseur, P., Aristarkhov, A., and Lee, J.T. (2010). Locked nucleic acids (LNAs). reveal sequence requirements and kinetics of Xist RNA localization to the X chromosome. Proc. Natl. Acad. Sci. USA 107, 22196-22201.
61. Sherr, C.J. and Roberts, J.M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512.
62. Simo-Riudalbas, L. and Esteller, M. (2014). Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br. J. Pharmacol. DOI: 10.1111/bph.12844.
63. Srikantan, V., Zou, Z., Petrovics, G., Xu, L., Augustus, M., Davis, L., Livezey, J.R., Connell, T., Sesterhenn, I.A., Yoshino, K., et al. (2000). PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 97, 12216-12221.
64. Stevens, M., De Clercq, E., and Balzarini, J. (2006). The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med. Res. Rev. 26, 595-625.
65. Takayama, K., Tsutsumi, S., Katayama, S., Okayama, T., Horie-Inoue, K., Ikeda, K., Urano, T., Kawazu, C., Hasegawa, A., Ikeo, K., et al. (2011). Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30, 619-630.
66. Takayama, K., Horie-Inoue, K., Katayama, S., Suzuki, T., Tsutsumi, S., Ikeda, K., Urano, T., Fujimura, T., Takagi, K., Takahashi, S., et al. (2013). Androgen-responsive long noncoding RNA CTBP1- AS promotes prostate cancer. EMBO J. 32, 1665-1680.
67. Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S.M., Ala, U., Karreth, F., Poliseno, L., Provero, P., Di Cunto, F., et al. (2011). Codingindependent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147, 344-357.
68. Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
69. Wang, L., Han, S., Jin, G., Zhou, X., Li, M., Ying, X., Wang, L., Wu, H., and Zhu, Q. (2014). Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgendependence to androgen-independence. Int. J. Oncol. 44, 2041-2049.
70. Weakley, S.M., Wang, H., Yao, Q., and Chen, C. (2011). Expression and function of a large non-coding RNA gene XIST in human cancer. World J. Surg. 35, 1751-1756.
71. Weischenfeldt, J., Simon, R., Feuerbach, L., Schlangen, K., Weichenhan, D., Minner, S., Wuttig, D., Warnatz, H.J., Stehr, H., Rausch, T., et al. (2013). Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159-170.
72. Wheeler, T.M., Leger, A.J., Pandey, S.K., MacLeod, A.R., Nakamori, M., Cheng, S.H., Wentworth, B.M., Bennett, C.F., and Thornton, C.A. (2012). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115.
73. Yang, L., Lin, C., Jin, C., Yang, J.C., Tanasa, B., Li, W., Merkurjev, D., Ohgi, K.A., Meng, D., Zhang, J., et al. (2013). lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500, 598-602.
74. Yap, K.L., Li, S., Munoz-Cabello, A.M., Raguz, S., Zeng, L., Mujtaba, S., Gil, J., Walsh, M.J., and Zhou, M.M. (2010). Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell 38, 662-674.
75. Yin, H., Xue, W., Chen, S., Bogorad, R.L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P.A., Jacks, T., and Anderson, D.G. (2014). Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551-553.
76. Zhao, J., Ohsumi, T.K., Kung, J.T., Ogawa, Y., Grau, D.J., Sarma, K., Song, J.J., Kingston, R.E., Borowsky, M., and Lee, J.T. (2010). Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol. Cell 40, 939-953.
77. Zhou, Y.L., Zhang, X., and Klibanski, A. (2012). MEG3 noncoding RNA: a tumor suppressor. J. Mol. Endocrinol. 48, R45-R53.